



**2017 Alliance Fall Group Meeting**  
Loews Chicago O'Hare Hotel – Rosemont, IL

## **Multiple Myeloma Committee Meeting Agenda**

Saturday, November 4  
8:30am-12:30pm CT

---

**Location**  
Loews Chicago O'Hare  
Cassat A and B

**Dial-in Information**  
Dial-in #: 800-501-8979  
Access code: 0739814

---

Chair: Paul Richardson, MD  
Vice-Chair: Phil McCarthy, MD

### **I. Welcome and Introductions**

### **II. Update from the Committee Chairs Meeting**

### **III. Alliance and Related Studies – Completed and Ongoing**

- a. CALGB 100104 and derived studies in ND MM/SCT  
*Sarah Holstein, MD, PhD; University of Nebraska Medical Center*  
*Phil McCarthy, MD; Roswell Park Cancer Institute*
- b. CALGB 100001: Seq chemo, ST1571 & transplant in Ph+ ALL  
*Sarah Holstein, MD, PhD; University of Nebraska Medical Center*
- c. IFM/DFCI 2009 Study in ND MM (BMT CTN 1304; the Determination trial)  
*Paul Richardson, MD; Dana-Farber Cancer Institute*
- d. A061202: Pom/Dex +/- MLN9708 in RR MM  
*Peter Voorhees, MD; Levine Cancer Institute*
- e. A061402: Plasmacytoma  
*Anuj Mahindra, MD; Scripps Cancer Center*
- f. AFT-29: RVd + Dara in SCT-eligible ND MM patients (the Griffin trial)  
*Peter Voorhees, MD; Levine Cancer Institute*  
*Jacob Laubach, MD; Dana-Farber Cancer Institute*  
*Paul Richardson, MD; Dana-Farber Cancer Institute*

### **IV. Endorsed Studies**

- a. ECOG – E1A11: RVd vs KRd in ND MM  
*Edward Faber, MD; Oncology Hematology Care Inc.*
- b. ECOG – E3A06: Smoldering myeloma study (lenalidomide vs placebo)  
*Anuj Mahindra, MD; Scripps Cancer Center*

- c. SWOG – S1211: RVD +/- Elo vs KRd +/- Elo for high risk ND MM  
*Peter Voorhees, MD; Levine Cancer Institute*
- d. SWOG – S1304: Carfilzomib in RR MM (completed; results pending)  
*Peter Voorhees, MD; Levine Cancer Institute*
- e. BMT CTN 1302: RIC allo followed by ixazomib maintenance in newly diagnosed MM  
*Cristina Gasparetto, MD; Duke Cancer Institute*

**V. Alliance Studies – Pending Activation/In Development**

- a. AFT-15: Ibrutinib + Rd in relapsed/refractory MM  
*Yvonne Efebera, MD; Ohio State University Medical Center*  
*Jacob Laubach, MD; Dana-Farber Cancer Institute*
- b. AFT-35: PVd Dara in relapsed/refractory MM  
*Hani Hassoun, MD; Memorial Sloan-Kettering Cancer Center*  
*Paul Richardson, MD; Dana-Farber Cancer Institute*
- c. AFT-40: Rev +/- multiple agents as maintenance post-ASCT  
*Sarah Holstein, MD, PhD; University of Nebraska Medical Center*  
*Phil McCarthy, MD; Roswell Park Cancer Institute*
- d. AFT-41: RID +/- Dara in non-SCT eligible newly diagnosed MM patients  
*Jacob Laubach, MD; Dana-Farber Cancer Institute*  
*Betsy O'Donnell, MD; Massachusetts General Hospital*  
*Paul Richardson, MD; Dana-Farber Cancer Institute*  
*Noopur Raje, MD; Massachusetts General Hospital*

**VI. New Concepts/Initiatives: Updates and New Proposals**

- a. Therapeutic Subcommittee in MM Older Adults  
*Tanya Wildes, MD; Washington University School of Medicine*  
*Sascha Tuchman, MD; University of North Carolina*  
*Ashley Rosko, MD; Ohio State University Medical Center*  
*Betsy O'Donnell, MD; Massachusetts General Hospital*
- b. Optimal duration of lenalidomide maintenance in MRD negative patients post ASCT  
*Peter Voorhees, MD; Levine Cancer Institute*
- c. Twice a week ixazomib + pom for relapsed/refractory MM  
*Paul Richardson, MD; Dana-Farber Cancer Institute*
- d. **New Ideas and Concepts**  
*All Members of the Committee*